Antibacterial picolinamide compounds
AssigneeUniversity of Notre Dame du Lac
InventorsShahriar MOBASHERY, Mayland CHANG, Enrico SPERI
Life of this patent
Estimating the term…
Loading patent…
AssigneeUniversity of Notre Dame du Lac
InventorsShahriar MOBASHERY, Mayland CHANG, Enrico SPERI
Estimating the term…
Here we report the discovery of 2-(4-(3-(trifluoromethoxy)phenoxy)picolinamido)benzo[d]oxazole-5-carboxylate as an antibacterial with potent and selective activity against C. difficile. Its MIC50 and MIC90 values, documented across 101 strains of C. difficile, are 0.12 and 0.25 μg/mL, respectively. The compound is effective against C. difficile both at the logarithmic (vegetative) and stationary phases of growth. It targets cell-wall biosynthesis, as assessed both by macromolecular biosynthesis assays and by scanning-electron microscopy. Animals infected with a lethal dose of C. difficile and treated with compound 1 had better survival compared to treatment with vancomycin, which is the front-line antibiotic used for severe recurrent C. difficile infection.
A compound of Formula I:
Dependencies are inferred from the claim text.